220 related articles for article (PubMed ID: 2728673)
1. [The value of CA 125 determination in the serum of patients with ovarian cancer].
Bartel U; Johannsen B; Elling D
Zentralbl Gynakol; 1989; 111(5):301-9. PubMed ID: 2728673
[TBL] [Abstract][Full Text] [Related]
2. [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors].
Crombach G; Zippel HH; Würz H
Geburtshilfe Frauenheilkd; 1985 Apr; 45(4):205-12. PubMed ID: 2408962
[TBL] [Abstract][Full Text] [Related]
3. [Initial experiences with CA-15-3 determination in the serum of patients with breast cancer].
Bartel U; Johannsen B; Reiss H; Elling D
Zentralbl Gynakol; 1989; 111(21):1417-24. PubMed ID: 2557715
[TBL] [Abstract][Full Text] [Related]
4. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
[TBL] [Abstract][Full Text] [Related]
5. [Results of CA-125 tumor marker determination in patients with ovarian carcinoma].
Miladinović D; Paunović R; Paunković N
Jugosl Ginekol Perinatol; 1989; 29(3-4):83-5. PubMed ID: 2601371
[TBL] [Abstract][Full Text] [Related]
6. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
Göcze P; Vahrson H
Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
[TBL] [Abstract][Full Text] [Related]
7. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
9. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
10. Tissue polypeptide specific antigen and cancer associated serum antigen in the follow-up of ovarian cancer.
Sliutz G; Tempfer C; Kainz C; Mustafa G; Gitsch G; Koelbl H; Biegelmayer C
Anticancer Res; 1995; 15(3):1127-9. PubMed ID: 7645936
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].
Sevelda P; Salzer H; Dittrich C; Spona J
Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):769-73. PubMed ID: 3865860
[TBL] [Abstract][Full Text] [Related]
12. The role of the CA 125 assay in the management of ovarian cancer.
Niloff JM
Oncology (Williston Park); 1988 Aug; 2(8):67-76. PubMed ID: 3275060
[TBL] [Abstract][Full Text] [Related]
13. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
14. [Tumor marker combination versus second-look operation in ovarian cancer].
Lahousen M; Stettner H; Pürstner P; Pickel H
Zentralbl Gynakol; 1990; 112(9):561-6. PubMed ID: 2378187
[TBL] [Abstract][Full Text] [Related]
15. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
[TBL] [Abstract][Full Text] [Related]
16. Relationship between saliva and serum CA 125 in women with and without epithelial ovarian cancer.
Plante M; Wong GY; Nisselbaum JS; Almadrones L; Hoskins WJ; Rubin SC
Obstet Gynecol; 1993 Jun; 81(6):989-92. PubMed ID: 8497368
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
18. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
[TBL] [Abstract][Full Text] [Related]
19. [Application of monoclonal antibody OC 125 in gynecological oncology].
Wu AR; Wang EY; Wang XX; Jia XH; Li L
Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
[TBL] [Abstract][Full Text] [Related]
20. [Tumor markers in gynecologic diseases].
Geyer H; Kleine W
Geburtshilfe Frauenheilkd; 1987 Mar; 47(3):168-72. PubMed ID: 3472991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
